Pfizer announced that the FDA has accepted for review its New Drug Application (NDA) for tofacitinib for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). The NDA is based on previously completed Phase 3 trials.

Tofacitinib is an oral Janus kinase (JAK) inhibitor that is being investigated as a targeted immunomodulator and disease-modifying therapy for RA.

For more information, call (800) 438-1985 or visit www.pfizer.com.